^
    2d
    TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=52, Recruiting, University of California, Davis | Not yet recruiting --> Recruiting | Trial completion date: Dec 2030 --> Feb 2030
    Enrollment open • Trial completion date
    |
    Adstiladrin (nadofaragene firadenovec-vncg)
    8d
    Gene Therapy for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: Current Evidence and Future Directions. (PubMed, Cancers (Basel))
    Nadofaragene firadenovec, a recombinant adenovirus delivering interferon alpha-2b (IFNα2b), is the first FDA-approved gene therapy for BCG-unresponsive NMIBC with carcinoma in situ (CIS)...Cretostimogene grenadenorepvec (CG0070), an oncolytic vector, demonstrated a 47% 6-month CR rate in a phase II study (NCT02365818). Detalimogene voraplasmid (EG-70), a nonviral gene therapy, demonstrated a 47% 6-month CR in a phase I/II study (NCT04752722). Future advances are likely to focus on patient selection, novel vectors, and combination strategies to improve treatment outcomes. Gene therapy represents a significant addition to the bladder cancer treatment landscape by offering bladder-sparing alternatives where conventional therapies are limited.
    Review • Journal
    |
    IFNA1 (Interferon Alpha 1)
    |
    Adstiladrin (nadofaragene firadenovec-vncg) • cretostimogene grenadenorepvec (CG0070) • detalimogene voraplasmid (EG-70)
    2ms
    iinnovate-1: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=272, Terminated, Takeda | Completed --> Terminated; Terminated by the sponsor for strategic reasons
    Trial termination
    |
    dexamethasone injection • modakafusp alfa (TAK-573)
    2ms
    EFFECTS OF TREATMENT WITH TEMSIROLIMUS VERSUS INTERFERON ALPHA ON SURVIVAL OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA - SINGLE-CENTER REAL-WORLD EXPERIENCE. (PubMed, Acta Clin Croat)
    In conclusion, temsirolimus therapy had a significantly positive effect on survival in patients with mRCC. Patients treated with temsirolimus showed significantly longer median survival and median PFS compared to patients treated with IFN-alpha.
    Clinical • Retrospective data • Journal • Real-world evidence
    |
    IFNA1 (Interferon Alpha 1)
    |
    Torisel (temsirolimus) • Roferon A (recombinant interferon alfa-2a)
    2ms
    ABLE-32: Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P3, N=454, Recruiting, Ferring Pharmaceuticals | Trial completion date: Mar 2030 --> Jun 2031 | Trial primary completion date: Mar 2030 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Adstiladrin (nadofaragene firadenovec-vncg)
    2ms
    PETALs: Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients (clinicaltrials.gov)
    P3, N=200, Completed, Hospices Civils de Lyon | Unknown status --> Completed
    Trial completion
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    Tasigna (nilotinib) • Pegasys (pegylated interferon α -2a)
    2ms
    TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=52, Not yet recruiting, University of California, Davis
    New P1 trial
    |
    Adstiladrin (nadofaragene firadenovec-vncg)
    3ms
    Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC) (clinicaltrials.gov)
    P3, N=25, Active, not recruiting, Ferring Pharmaceuticals | Trial primary completion date: Oct 2025 --> Nov 2029
    Trial primary completion date
    |
    Adstiladrin (nadofaragene firadenovec-vncg)
    3ms
    ABLE-41: ADSTILADRIN Early Utilization and Outcomes in the Real World Setting (clinicaltrials.gov)
    P=N/A, N=400, Recruiting, Ferring Pharmaceuticals | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date • Real-world evidence
    |
    Adstiladrin (nadofaragene firadenovec-vncg)
    4ms
    iinnovate-2: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=15, Terminated, Takeda | Completed --> Terminated; Due to strategic reasons (no safety concerns).
    Trial termination
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • carfilzomib • pomalidomide • modakafusp alfa (TAK-573)
    4ms
    iinnovate-3: A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=15, Terminated, Takeda | Completed --> Terminated; After completion of Phase 1 Dose Escalation of this study the sponsor decided not to proceed with Phase 2a due to strategic reasons. Thus, no participants were enrolled for Phase 2a and the study was terminated early.
    Trial termination
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj) • modakafusp alfa (TAK-573)
    5ms
    Successful treatment of depressed esophageal squamous papilloma with interferon- alpha 2a: A case report. (PubMed, World J Clin Cases)
    This paper reports the first successful clinical case of using the human IFNα2a for the treatment of ESP with a depressed endoscopic appearance. However, the efficacy of interferon treatment requires to validation in a large number of subsequent cases.
    Journal
    |
    IFNA1 (Interferon Alpha 1)
    |
    Roferon A (recombinant interferon alfa-2a)